Management Team
Seungil Ro - President and CSO
Seungil Ro, Ph.D. founded RosVivo Therapeutics in
2021 and is its President and CSO. In 2022, he secured
funds for preclinical studies of therapeutic microRNAs
to treat diabetes.
Dr. Ro holds 7 US/International Patents for the treatment of diabetes, obesity, fatty liver disease, and gastrointestinal dysmotility.
He is also a Professor in the Department of Physiology & Cell Biology at the University of Nevada School of Medicine, Reno, Nevada.
Dr. Ro has published 70 articles in multiple high-impact journals including Nature Genetics, Cell Research, Gut, and Gastroenterology, on topics relating to genetic and epigenetic regulation in diabetes, gastrointestinal motility disorders, and cancers.
Dr. Ro holds 7 US/International Patents for the treatment of diabetes, obesity, fatty liver disease, and gastrointestinal dysmotility.
He is also a Professor in the Department of Physiology & Cell Biology at the University of Nevada School of Medicine, Reno, Nevada.
Dr. Ro has published 70 articles in multiple high-impact journals including Nature Genetics, Cell Research, Gut, and Gastroenterology, on topics relating to genetic and epigenetic regulation in diabetes, gastrointestinal motility disorders, and cancers.
Dr. Jonathan Hull - CEO
Dr. Hull is a leader in the business of science. After graduating from Yale with a Ph.D. in Chemistry, he received the Distinguished Goldhaber Fellowship at Brookhaven National Lab where he
published in Nature.
His corporate career began in identifying growth technologies for a Fortune 500 company, then expanded to marketing, sales, finance and M&A with a private equity rollup. This equipped him to co-found and become CEO of a venture-backed startup in 2016, which was acquired in 2022.
He is passionate about innovation, new venture creation and making friends in the process.
His corporate career began in identifying growth technologies for a Fortune 500 company, then expanded to marketing, sales, finance and M&A with a private equity rollup. This equipped him to co-found and become CEO of a venture-backed startup in 2016, which was acquired in 2022.
He is passionate about innovation, new venture creation and making friends in the process.
Sandra M. Poudrier - COO
Sandra has 25 years of experience in biotech in all aspects of product lifecycles from basic research to scale-up, cGMP manufacturing, product validation, and post-marketing product support, She has a patent for a diagnostic assay for pancreatitis. Sandra was also an original member of Dr. Ro's research team which discovered the regulatory role miRNAs have on gut motility, diabetes, and obesity,
Prior to working with Dr. Ro, Sandra was the Director of Quality for two divisions of a multi-national company and was responsible for the development, oversight, and execution of their international regulatory and quality systems whose served multinational customers such as ExxonMobil, Chevron Corporations and KOGAS.
Prior to working with Dr. Ro, Sandra was the Director of Quality for two divisions of a multi-national company and was responsible for the development, oversight, and execution of their international regulatory and quality systems whose served multinational customers such as ExxonMobil, Chevron Corporations and KOGAS.